Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide and hydroxychloroquine combination therapy for primary Sjogren's syndrome
2014-003140-12Phase 3Active
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of leflunomide and hydroxychloroquine in Sjögren's syndrome (SS), sponsored by University Medical Center Utrecht. Primary endpoint: Improvement of disease activity measured by ESSDAI. Started Aug 2015; status: active.
02
Drugs
leflunomidehydroxychloroquine
03
Conditions
Sjögren's syndrome (SS)
Beyond the preview
Go deeper on 2014-003140-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003140-12.